Association between polymorphisms of CYP2J2 and EPHX2 genes and risk of coronary artery disease

Pharmacogenetics and Genomics

Volumn 21, Issue 8, 2011, Pages 489-494

  Xu, Yujun ^a   Ding, Hu ^a   Peng, Jia ^a   Cui, Guanglin ^a   Liu, Lei ^a   Cianflone, Katherine ^b   Wang, Dao Wen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

association; coronary artery disease; CYP2J2; EPHX2; G 50T; R287Q; single nucleotide polymorphism

Indexed keywords

CYTOCHROME P450 2J2; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE 2; GENOMIC DNA; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79960840423     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283485eb2     Document Type: Article

References (44)

1. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, et al. Genome-wide association analysis of coronary artery disease. N Engl J Med 2007; 357:443-453. (Pubitemid 47204873)
2. Samani NJ, Deloukas P, Erdmann J, Hengstenberg C, Kuulasmaa K, McGinnis R, et al. Large scale association analysis of novel genetic loci for coronary artery disease. Arterioscler Thromb Vasc Biol 2009; 29:774-780.
3. McPherson R. A gene-centric approach to elucidating cardiovascular risk. Circ Cardiovasc Genet 2009; 2:3-6.
4. Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 2006; 6:947-960. (Pubitemid 44862679)
5. Gross GJ, Falck JR, Gross ER, Isbell M, Moore J, Nithipatikom K. Cytochrome P450 and arachidonic acid metabolites: role in myocardial ischemia/reperfusion injury revisited. Cardiovasc Res 2005; 68:18-25. (Pubitemid 41253552)
6. Yousif MH, Benter IF. Role of cytochrome P450 metabolites of arachidonic acid in regulation of corporal smooth muscle tone in diabetic and older rats. Vascul Pharmacol 2007; 47:281-287. (Pubitemid 350008129)
7. Yousif MH, Benter IF, Roman RJ. Cytochrome P450 metabolites of arachidonic acid play a role in the enhanced cardiac dysfunction in diabetic rats following ischaemic reperfusion injury. Auton Autacoid Pharmacol 2009; 29:33-41.
8. Theken KN, Lee CR. Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk. Pharmacogenomics 2007; 8:1369-1383. (Pubitemid 350162851)
9. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-874. (Pubitemid 36019640)
10. Fleming I, Michaelis UR, Bredenkotter D, Fisslthaler B, Dehghani F, Brandes RP, et al. Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 2001; 88:44-51. (Pubitemid 32064081)
11. Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, et al. The antiinflammatory effect of laminar flow: the role of PPAR gamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci USA 2005; 102:16747-16752. (Pubitemid 41688848)
12. Moshal KS, Zeldin DC, Sithu SD, Sen U, Tyagi N, Kumar M, et al. Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhibition of NF-kappa beta in hyperhomocysteinemia. J Cell Physiol 2008; 215:771-781. (Pubitemid 351632699)
13. Deng Y, Theken KN, Lee CR. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. J Mol Cell Cardiol 2010; 48:331-341.
14. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 2001; 276:36059-36062.
15. Zordoky BN, El-Kadi AO. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther 2010; 125:446-463.
16. Wang YX, Ulu A, Zhang LN, Hammock B. Soluble epoxide hydrolase in atherosclerosis. Curr Atheroscler Rep 2010; 12:174-183.
17. Ding H, Cui G, Zhang L, Xu Y, Bao X, Tu Y, et al. Association of common variants of CYP4A11 and CYP4F2 with stroke in the Han Chinese population. Pharmacogenet Genomics 2010; 20:187-194.
18. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70:425-434. (Pubitemid 34112296)
19. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265. (Pubitemid 40202029)
20. Gonzalez JR, Armengol L, Sole X, Guino E, Mercader JM, Estivill X, et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics 2007; 23:644-645. (Pubitemid 46522604)
21. Gauderman W, Morrison J. Quanto 1.1: a computer program for power and sample size calculations for genetic-epidemiology studies, http://hydra.usc.edu/ gxe. 2006.
22. Munafo MR, Flint J. Meta-analysis of genetic association studies. Trends Genet 2004; 20:439-444. (Pubitemid 39094573)
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560. (Pubitemid 37088507)
24. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127:820-826. (Pubitemid 27465551)
25. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634. (Pubitemid 27387172)
26. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50:1088-1101.
27. Marciante KD, Totah RA, Heckbert SR, Smith NL, Lemaitre RN, Lumley T, et al. Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke. Pharmacogenet Genomics 2008; 18:535-543. (Pubitemid 351769921)
28. Borgel J, Bulut D, Hanefeld C, Neubauer H, Mugge A, Epplen JT, et al. The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile. BMC Cardiovasc Disord 2008; 8:41.
29. Fava C, Montagnana M, Almgren P, Hedblad B, Engstrom G, Berglund G, et al. The common functional polymorphism-50GT of the CYP2J2 gene is not associated with ischemic coronary and cerebrovascular events in an urban-based sample of Swedes. J Hypertens 2010; 28: 294-299.
30. Lung A, Yu L, Chi J, Chun L, Chi T. G-50T Polymorphism of the cytochrome P450 epoxygenase CYP2J2 gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Acta Cardiol Sin 2006; 22: 148-153.
31. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the atherosclerosis risk in communities (ARIC) study. Pharmacogenet Genomics 2007; 17:349-358. (Pubitemid 46608542)
32. Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004; 110: 2132-2136. (Pubitemid 39372490)
33. Hoffmann MM, Bugert P, Seelhorst U, Wellnitz B, Winkelmann BR, Boehm BO, et al. The-50GT polymorphism in the promoter of the CYP2J2 gene in coronary heart disease: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem 2007; 53:539-540. (Pubitemid 46447958)
34. Liu PY, Li YH, Chao TH,Wu HL, Lin LJ, Tsai LM, et al. Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis 2007; 195: 199-206.
35. Lee J, Dahl M, Grande P, Tybjaerg-Hansen A, Nordestgaard BG. Genetically reduced soluble epoxide hydrolase activity and risk of stroke and other cardiovascular disease. Stroke 2010; 41:27-33.
36. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, et al. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 2006; 15:1640-1649. (Pubitemid 43904830)
37. Fava C, Montagnana M, Danese E, Almgren P, Hedblad B, Engstrom G, et al. Homozygosity for the EPHX2 K55R polymorphism increases the longterm risk of ischemic stroke in men: a study in Swedes. Pharmacogenet Genomics 2010; 20:94-103.
38. Sandberg M, Hassett C, Adman ET, Meijer J, Omiecinski CJ. Identification and functional characterization of human soluble epoxide hydrolase genetic polymorphisms. J Biol Chem 2000; 275:28873-28881.
39. Wei Q, Doris PA, Pollizotto MV, Boerwinkle E, Jacobs DR Jr, Siscovick DS, et al. Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking. Atherosclerosis 2007; 190:26-34. (Pubitemid 44920229)
40. Fornage M, Boerwinkle E, Doris PA, Jacobs D, Liu K, Wong ND. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 2004; 109: 335-339. (Pubitemid 38133900)
41. Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 2000; 53:207-216. (Pubitemid 30151226)
42. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006; 333:597-600. (Pubitemid 44433638)
43. Cordell HJ, Clayton DG. Genetic association studies. Lancet 2005; 366: 1121-1131. (Pubitemid 41338767)
44. Clayton D, McKeigue PM. Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet 2001; 358: 1356-1360. (Pubitemid 33016504)